Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology
Sep 13
- Sep 17, 2024
Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study
Wilky, et al.
Filter by
INCAGN1949 (OX40 Agonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
INCAGN01949: A Novel Anti-OX40 Agonist Antibody With the Potential to Enhance Tumor Specific T-cell Responsiveness, While Selectively Depleting Intratumoral Regulatory T Cells.
Gonzalez, et al.
INCAGN1949 (OX40 Agonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
INCAGN1949, an Anti-OX40 Antibody With an Optimal Agonistic Profile and the Ability to Selectively Deplete Intratumoral Regulatory T Cells.
Gonzalez, et al.
INCAGN1876 (GITR Agonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
A Novel Agonist Antibody (INCAGN01876) That Targets the Costimulatory Receptor GITR.
Gonzalez, et al.
INCAGN1876 (GITR Agonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
INCAGN1876, a Unique GITR Agonist Antibody That Facilitates GITR Oligomerization.
Gonzalez, et al.
INCAGN2390 (TIM-3 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3.
Waight, et al.
INCAGN2385 (LAG-3 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies.
Savitsky, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Frontiers in Immunology
Oct 22, 2019
TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing.
Burcu, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
Identification and characterization of an allogeneic iNKT-CAR targeting BCMA.
Michelet, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models.
Yigit, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product.
Purbhoo, et al.